Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-based vs Trough Concentration-based Dosing of Infliximab

The trough concentration adapted infliximab treatment (TAXIT) trial demonstrated that maintaining infliximab trough concentrations at 3–7 μg/mL is most effective at inducing remission in patients with inflammatory bowel diseases (IBD), with fewer flares than clinic-based dosing. We performed a follow-up analysis of study participants to explore the correlation between trough dosing strategy and mucosal healing, continued infliximab use, and rates of hospitalization, surgery, and steroid use.

http://ift.tt/2jDfzNP